Thomas Taapken - InflaRx NV Chief Officer
| IFRX Stock | USD 2.36 0.05 2.16% |
Insider
Thomas Taapken is Chief Officer of InflaRx NV
| Age | 59 |
| Address | Winzerlaer Str. 2, Jena, Germany, 07745 |
| Phone | 49 3641 508 180 |
| Web | https://www.inflarx.de |
InflaRx NV Management Efficiency
The company has return on total asset (ROA) of (0.2198) % which means that it has lost $0.2198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4534) %, meaning that it created substantial loss on money invested by shareholders. InflaRx NV's management efficiency ratios could be used to measure how well InflaRx NV manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.37 in 2024. Return On Capital Employed is likely to drop to -0.46 in 2024. At this time, InflaRx NV's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to rise to about 4.3 M in 2024, whereas Total Assets are likely to drop slightly above 106.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Lauren White | C4 Therapeutics | N/A | |
| MS MBA | Inozyme Pharma | 47 | |
| Chulani Karunatilake | Werewolf Therapeutics | 64 | |
| Joo MD | Design Therapeutics | 61 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Prof MD | Fulcrum Therapeutics | N/A | |
| Cynthia SeidelDugan | Werewolf Therapeutics | 65 | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| ScD MD | Sellas Life Sciences | 48 | |
| Esther Rajavelu | Fulcrum Therapeutics | 45 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Aseem Ansari | Design Therapeutics | N/A | |
| Nik Chetwyn | Erasca Inc | N/A | |
| Jay MD | Eyepoint Pharmaceuticals | 65 | |
| Judith Dunn | Fulcrum Therapeutics | 62 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.22 |
InflaRx NV Leadership Team
Elected by the shareholders, the InflaRx NV's board of directors comprises two types of representatives: InflaRx NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of InflaRx. The board's role is to monitor InflaRx NV's management team and ensure that shareholders' interests are well served. InflaRx NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, InflaRx NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jan CFA, Head VP | ||
| Thomas Taapken, Chief Officer | ||
| Derval OCarroll, Senior Compliance | ||
| Igor Orshanskiy, Senior Development | ||
| Maria Habel, Head RD | ||
| Christian Schmid, VP Counsel | ||
| Kofi Boaten, Senior Supplies | ||
| Bruce Burnett, VP Affairs | ||
| Pr MD, Chief CoFounder | ||
| Camilla MD, Chief Officer | ||
| Evelyn RothGeissler, VP Operations | ||
| Nicole Bertsch, Senior Resources | ||
| Petra Esser, VP Controlling | ||
| Kafi Boaten, Director Supplies | ||
| Peter Hurt, Director Pharmacovigiliance |
InflaRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is InflaRx NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 79.28 M | ||||
| Shares Outstanding | 58.88 M | ||||
| Shares Owned By Insiders | 7.34 % | ||||
| Shares Owned By Institutions | 22.52 % | ||||
| Number Of Shares Shorted | 157.04 K | ||||
| Price To Earning | (7.90) X | ||||
| Price To Book | 2.03 X | ||||
| Price To Sales | 1,317 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.